InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

InspireMD Price Performance

NSPR stock opened at $1.89 on Wednesday. The stock has a market capitalization of $44.23 million, a price-to-earnings ratio of -1.75 and a beta of 0.83. The business has a fifty day moving average price of $2.38 and a 200 day moving average price of $2.68. InspireMD has a fifty-two week low of $1.03 and a fifty-two week high of $3.85.

InspireMD (NYSE:NSPR) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.65 million. During the same quarter in the previous year, the company posted ($0.60) EPS. On average, equities analysts expect that InspireMD will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Avestar Capital LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $65,000. Avestar Capital LLC owned 0.09% of InspireMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.